ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer.

Antonia K RoseweirElaine S HalcrowSergey ChichiloArfon Gethyn Morgan Tregellis PowellDonald C McMillanPaul G HorganJoanne Edwards

Published in: British journal of cancer (2018)

MMR-competent stage III tumours harbouring BRAF mutations have an improved prognosis when strong nuclear phosphorylation of both ERK and p38MAPK is present.

Keyphrases

wild type
signaling pathway
pi k akt
cell proliferation
metastatic colorectal cancer
protein kinase
free survival